Article Type
Review
Published
This article aims to review the current knowledge on deucravacitinib, a new oral small molecule that selectively inhibits tyrosine kinase 2 (TYK2), for the treatment of psoriatic arthritis.
Review
This article aims to review the current knowledge on deucravacitinib, a new oral small molecule that selectively inhibits tyrosine kinase 2 (TYK2), for the treatment of psoriatic arthritis.
Case Report
We present four clinical reports that illustrate the clinical uses of GMA with the medical device Adacolumn® in patients with different backgrounds and immune-mediated inflammatory arthritis.
Editorial
Bimekizumab is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one of the drugs to be observed in 2021. This article discusses the current status of bimekizumab.
Original Research
The objective of this study was to detect and correlate the changes that indicate the inflammatory and atherosclerotic process in psoriasis and psoriatic arthritis patients, using nail ultrasound and carotid artery intima–media thickness radiofrequency software.
Review
This article reviews brodalumab’s place in the expanding armamentarium of cytokine-directed therapies for patients with severe psoriasis.